Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials

Diabetes Obes Metab. 2021 Apr;23(4):1063-1065. doi: 10.1111/dom.14297. Epub 2020 Dec 29.

Authors

Dimitrios Patoulias¹, Christodoulos Papadopoulos², Michael Doumas^{1

3}

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.
² Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.
³ Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia, USA.

PMID: 33319468
DOI: 10.1111/dom.14297

No abstract available

Publication types

Letter
Meta-Analysis

MeSH terms

Amputation, Surgical
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Humans
Hypoglycemic Agents / adverse effects
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
Symporters*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
Glucose